Showing 2211-2220 of 10613 results for "".
Histopathologic Assessment of Atypical Pigmented Lesions: Financial and Diagnostic Considerations
https://practicaldermatology.com/topics/skin-cancer-photoprotection/histopathologic-assessment-of-atypical-pigmented-lesions-financial-and-diagnostic-considerations/21335/Taking prospective deeper sections may prove more cost-efficient in the long-term.Why Lutronic
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/why-lutronic/19188/Established in 1997 by a group of accomplished scientists and prominent members of the medical community, LUTRONIC is passionate about improving the lives of physicians and their patients by developing solutions that are intuitive, versatile, and efficacious. Our customers choose our systems becauseDevices in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/devices-in-dermatology/22955/The State of the ArtTake 5: Clinically-Relevant Findings About Causes and Treatment of Rosacea
https://practicaldermatology.com/columns/take-5/take-5-clinically-relevant-findings-about-causes-and-treatment-of-rosacea/21870/Research sheds light on the pathogenesis of the disease and patients' experience.Take 5: Promising Developments in Vitiligo Research
https://practicaldermatology.com/columns/take-5/promising-developments-in-vitiligo-research/21924/New studies suggest therapeutic pearls for the management of vitiligo and highlight new approaches to understanding the disorder.Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
https://practicaldermatology.com/programs/cme/hitting-the-target-in-atopic-dermatitis-interdisciplinary-team-training-for-leveraging-il-13-inhibitors-to-address-the-burden-of-disease/54437/On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.GLP-1RAs and the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1ras-and-the-dermatologist/48885/We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation.The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.From Training to Transformation: How Leaders Get the Most Out of Educating Their Team
https://practicaldermatology.com/issues/september-2025/from-training-to-transformation-how-leaders-get-the-most-out-of-educating-their-team/37640/Imagine investing thousands of dollars in staff time and tuition for the latest aesthetic techniques or business courses—sending employees to conferences or bringing in an expert for in-office training—only to watch those skills fade, or be underused or forgotten.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at Take